ENDOCRINOLOGY Flashcards
ADA recommendation for diabetes screening
>45 years every 3 years
* Screening should be earlier if overweight (BMI>25) + one additional risk factors for DM
Most common pattern of dyslipidemia in DM
hypertriglyceridemia and reduced high-density lipoprotein (HDL)
best initial therapy for type 2 diabetes.
Diet, exercise, and weight loss
preferred initial pharmacologic agent for T2DM
Metformin
DM drugs that promotes weight gain
o Sulfonylureas
o TZD
o Insulin
Promotes weight loss
o Metformin
o SGLT2 inhibitor
o GLP1 receptor agonist
Weight neutral drug
DPP-4 inhibitor
- Insulin secretagogues: increases insulin secretion
- can cause Hypoglycemia, Weight gain
Sulfonylureas (SU)
- Gliclazide
- Glibenclamide
- Glimepiride
- Glipizide
Non-Sulfonylureas
- Repaglinide
- Nateglinide
Insulin sensitizers
Biguanides - metformin
Thiazolidinediones - Pioglitazone
Inhibits intestinal absorption of sugars
Alpha-glucosidase inhibitors
- Acarbose
- Voglibose
- Miglitol
Incretin-related drugs: prolongs endogenous action of GLP-1
DPP-IV Inhibitors
- Sitagliptin Saxagliptin Linagliptin Vildagliptin
GLP-1 agonists
- Exenatide SC Liraglutide SC
Treatment goals for DM
Increases urinary glucose excretion
Na-Glucose Transporter-2inhibitors (SGLT2i)
- Dapagliglozin, Canagliflozin, Empagliflozin
first defense against hypoglycemia.
Decrease in insulin secretion
second defense against hypoglycemia; Epinephrine is third.
Glucagon
play no role in defense against acute hypoglycemia.
Cortisol and growth hormones
The most serious complication of therapy for DM
hypoglycemia
Drugs proven to decrease rate of progression of nephropathy
ACE inhibitors dilate the efferent arteriole and ↓ intraglomerular hypertension (ACE and ARB)
The most effective therapy for diabetic retinopathy
prevention
The most common form of diabetic neuropathy
distal symmetric polyneuropathy
one of the earliest signs of diabetic neuropathy
Erectile dysfunction and retrograde ejaculation
The most common skin manifestations of DM
xerosis and pruritus.
pathophysiology of DKA
Relative or absolute insulin deficiency combined with counterregulatory hormone excess (glucagon, catecholamines, cortisol, and growth hormone)
Triad of DKA
o Hyperglycemia
o Metabolic acidosis (high anion gap)
o Ketosis
predominant ketone in ketosis.
3-hydroxybutyrate
in DKA, once the blood glucose reaches 250 mg/dl, what fluid should be added?
D5 containing fluid
5 I’s for precipitating factors of DKA:
o Infection
o Ischemia
o Infarction
o Ignorance (poor control)
o Intoxication
The major nonmetabolic complication of DKA therapy
cerebral edema
* Sudden reduction in hyperglycemia can lead to vascular collapse with shift of water intracellularly
What symptoms are Notably absent in HHS compared to DKA?
nausea, vomiting, and abdominal pain and the Kussmaul respirations characteristics of DKA
Management of DKA/ HHS
Metabolic Syndrome definition
method of choice when it is important to determine thyroid size accurately
UTZ
What is the initial test of choice for hyperthyroidism?
TSH
When do you repeat thyroid function test after staring treatment?
4-6 weeks
What is the most common sign of thyrotoxicosis?
Tachycardia
ovarian tissues houses active thyroid tissues secreting FT4 and FT3. The ectopic thyroid tissue acts like a target organ hence classified as primary hyperthyroidism
Struma ovarii